Centessa Pharmaceuticals plc
CNTA
$12.30
$0.4653.93%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -56.04% | -2.44% | 8.86% | 34.84% | 30.12% |
| Total Depreciation and Amortization | 10.32% | 45.08% | 85.49% | 156.43% | 136.64% |
| Total Amortization of Deferred Charges | 20.00% | 69.66% | 195.10% | 1,057.69% | -- |
| Total Other Non-Cash Items | 705.61% | 597.68% | 336.09% | -53.58% | -51.82% |
| Change in Net Operating Assets | 217.71% | 77.95% | -27.95% | -234.48% | -608.43% |
| Cash from Operations | 11.40% | 27.95% | 19.85% | 24.49% | 20.05% |
| Capital Expenditure | 79.88% | 92.18% | 90.73% | 91.78% | 85.14% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 124.68% | 88.98% | 94.78% | 72.31% | -61,670.39% |
| Cash from Investing | 124.62% | 89.00% | 94.76% | 72.53% | -13,541.68% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1,656.08% | 2,405.09% | 42,876.00% | 8,153.26% | 2,841.09% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 1,627.29% | 2,379.96% | 42,026.46% | 8,153.26% | 4,520.79% |
| Foreign Exchange rate Adjustments | 99.51% | -225.42% | -115.64% | -40.82% | 247.13% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 196.08% | 181.78% | 94.73% | 50.16% | -31.86% |